Neoplasms

Heart and Blood Diseases

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Musculoskeletal Diseases

Symptoms and General Pathology

Rare Diseases

Multiple Myeloma

Neoplasms, Plasma Cell

Osteonecrosis

Bone Diseases

Osteolysis

Neoplasms by Histologic Type

Hemostatic Disorders

Blood Coagulation Disorders

Vascular Diseases

Paraproteinemias

Blood Protein Disorders

Hematologic Diseases

Hemorrhagic Disorders

Lymphoproliferative Disorders

Immunoproliferative Disorders

Bone Density Conservation Agents

All Drugs and Chemicals

Zoledronic Acid

treatment with zoledronic acid for 4 years

treatment with zoledronic acid withheld after two years

Zoledronic acid will be given to all participants for two years. Then patients will be randomized to A receive 2 more years of treatment or B stop treatment.

Zoledronic acid

Thomas LunD, MD Ph.D.

Main hypothesis: Patients who continue zoledronic acid after year 2 have longer time until progression in bone disease compared to patients who stop treatment after two years?

Secondary hypothesis: Serum will bone markers increase prior to progression in bone disease in the individual patient?

Secondary hypothesis: Low-dose CT will detect more cases of osteolytic bone disease in Multiple Myeloma compared to conventional radiography

Newly diagnosed myeloma patients will be followed for 4 years. The first two years they will be treated with zoledronic acid monthly. At year 2 they will be randomized to A continue treatment for 2 more years or B stop treatment. The primary outcome of the study will be time to progressive bone disease from year 2 and onward.

Serum bone markers will be measured throughout the study. In patients who experience progressive bone disease, development of bone markers prior to the radiological progression will be investigated to see the if it could have been predicted with the use of serum markers

During the four year period patients will have low-dose CT superior and conventional radiography made at predefined time points. The secondary outcome of the study is to compare the sensitivity of the two modalities

Prolonged Protection From Bone Disease in Multiple Myeloma

Magnolia Study Prolonged Protection From Bone Disease in Multiple Myeloma. An Open Label Phase 3 Multicenter International Randomised Trial

Patients will have low-dose CT and conventional x-ray made at predefined time points to compare the sensitivity between the two modalities

After two years of zoledronic acid treatment patients will be randomized to A continue treatment B stop treatment.

Development in bone markers prior to progression in osteolytic lesions will be investigated

Thomas Lund

MD Ph.D.

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Skin and Connective Tissue Diseases

Prostatic Neoplasms

Breast Neoplasms

Breast Diseases

Skin Diseases

Genital Neoplasms, Male

Urogenital Neoplasms

Genital Diseases

Genital Diseases, Male

Urogenital Diseases

Prostatic Diseases

Male Urogenital Diseases

Bone Resorption

Analgesics

Clodronic Acid

Random group of patients in oncology clinic

Clodronate (Bonefos, BAY94-8393)

Bayer Study Director

Adherence (or compliance with) a medication regimen is generally defined as the extent to which patients take medication as prescribed by their health care providers. The adherence to medications has close relation to effectiveness of the therapy. The primary objective of this study is to observe the adherence to treatment with oral clodronate (PDC, proportion of days covered, number of days in which clodronate is taken according to treating physician recommendation) in patients with malignancy. The secondary "hypothesis generating" objective is to describe the relation between adherence to treatment with oral clodronate and efficacy of the therapy (skeletal events, pain).

Study to Investigate Adherence of Patients to Clodronate (Bonefos) Treatment

BONA (Adherence of Patients to Bonefos Therapy). Prospective Observational Non-interventional Study of Adherence of Patients to Bonefos Medication in Relation to Analgesic Effect and Incidence of Skeletal Events

Bayer

Medical Director

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Prolonged Protection From Bone Disease in Multiple Myeloma	NCT02286830	Multiple Myelom...	Zoledronic acid	18 Years -	Odense University Hospital
Study to Investigate Adherence of Patients to Clodronate (Bonefos) Treatment	NCT01198457	Breast Neoplasm... Prostatic Neopl... Multiple Myelom... Osteolysis	Clodronate (Bon...	18 Years -	Bayer
Prolonged Protection From Bone Disease in Multiple Myeloma	NCT02286830	Multiple Myelom...	Zoledronic acid	18 Years -	Odense University Hospital
Prolonged Protection From Bone Disease in Multiple Myeloma	NCT02286830	Multiple Myelom...	Zoledronic acid	18 Years -	Odense University Hospital

Spots Global Cancer Trial Database for osteolysis

Every month we try and update this database with for osteolysis cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for osteolysis

Every month we try and update this database with for osteolysis cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for osteolysis cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.